From Passion Health Primary Care – Accurate, Action‑Oriented, Patient-Centered
Today’s news highlights the FDA’s green light on Elevidys gene therapy for ambulatory Duchenne patients, leadership changes within the agency, and continued measles concerns both in Texas and globally. Stay informed with Passion Health for clinically accurate, regionally relevant, and globally aware updates that matter to your health and your practice.
🇺🇸 National Updates
✅ FDA Okay to Resume Ambulatory Use of Elevidys Gene Therapy
After investigating, the FDA cleared Sarepta’s Elevidys gene therapy for ambulatory Duchenne muscular dystrophy patients. Shipments paused after safety concerns were removed, boosting confidence in the treatment’s use under careful monitoring. Use remains paused for non‑ambulatory patients.
✅ FDA’s Chief Medical Officer Prasad Departs
Vinay Prasad resigned shortly after Elevidys controversy. His exit follows pressure over FDA’s handling of the gene therapy pause and policy disagreements.
🏥 Texas Updates
✅ Texas Measles Cases Hold at ~762, Wastewater Signals Remain
The outbreak continues to dominate the national case count. Measles RNA detected in Austin wastewater without new clinical cases, suggesting possible silent transmission. Hospitalizations total 99, with two child fatalities. Vaccination rates in Travis County are under 90%.
🌍 Global Health Alerts
✅ Americas Region Sees Record Measles Surge
By mid‑June, the Pan American Health Organization reported 7,132 measles cases and 13 deaths across nine countries, including the U.S. and Mexico. Children under 5 are most affected.
💡 Clinical Tips for Providers
• Inform eligible Duchenne families that Elevidys deliveries for ambulatory patients have resumed; reinforce liver monitoring and risk counseling.
• Urge patients—especially in Travis County—to verify MMR status before school. Use wastewater surveillance signals to guide awareness.
• Screen pediatric and international travel patients from the Americas for measles symptoms and hydration evaluation.
